Sheila A Doggrell

Summary

Affiliation: RMIT University
Country: Australia

Publications

  1. ncbi request reprint Is rimonabant efficacious and safe in the treatment of obesity?
    Sheila A Doggrell
    RMIT University, School of Medical Sciences, Discipline of Pharmaceutical Sciences, Bundoora, Victoria 3083, Australia
    Expert Opin Pharmacother 9:2727-31. 2008
  2. ncbi request reprint Is tocilizumab an option for the treatment of arthritis?
    Sheila A Doggrell
    RMIT University, School of Medical Sciences, Discipline of Pharmaceutical Sciences, Bundoora, VIC3083, Australia
    Expert Opin Pharmacother 9:2009-13. 2008
  3. ncbi request reprint Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?
    Sheila A Doggrell
    RMIT University, Pharmaceutical Sciences, School of Medical Sciences, PO Box 71, Victoria 3083, Australia
    Expert Opin Pharmacother 9:405-20. 2008
  4. ncbi request reprint Celecoxib to prevent restenosis--results from the COREA-TAXUS trial
    Sheila A Doggrell
    RMIT University, Discipline of Pharmaceutical Sciences, School of Medical Sciences, Bundoora, Victoria 3083, Australia
    Expert Opin Pharmacother 9:339-41. 2008
  5. ncbi request reprint Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide
    Sheila A Doggrell
    School of Science, Faculty of Education, Health and Science, Charles Darwin University, Darwin, Northern Territory 0909, Australia
    Rev Recent Clin Trials 2:77-84. 2007
  6. ncbi request reprint Recent evidence of sustained benefit with exenatide in Type 2 diabetes
    Sheila A Doggrell
    School of Science, Charles Darwin University, Casuarina, Northern Territory 0811, Australia
    Expert Opin Pharmacother 7:2003-6. 2006
  7. ncbi request reprint Phosphoinositide 3-kinase-gamma as a target in rheumatoid arthritis and systemic lupus
    Sheila A Doggrell
    Charles Darwin University, School of Science, Casuarina, NT 0811, Australia
    Expert Opin Ther Targets 10:627-30. 2006
  8. ncbi request reprint Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?
    Sheila A Doggrell
    School of Science, Charles Darwin University, PO Box 41246, Casuarina, Northern Territory 0811, Australia
    Expert Opin Pharmacother 7:1229-33. 2006
  9. ncbi request reprint Inhibition of RANKL: a new approach to the treatment of osteoporosis
    Sheila A Doggrell
    School of Science, Charles Darwin University, Casuarina, Northern Territory 0811, Australia
    Expert Opin Pharmacother 7:1097-100. 2006
  10. ncbi request reprint Is exenatide advancing the treatment of type 2 diabetes?
    Sheila A Doggrell
    Division of Health Practice, Auckland University of Technology Akoranga Campus, Northcote, Auckland, New Zealand
    Expert Opin Pharmacother 7:109-12. 2006

Detail Information

Publications19

  1. ncbi request reprint Is rimonabant efficacious and safe in the treatment of obesity?
    Sheila A Doggrell
    RMIT University, School of Medical Sciences, Discipline of Pharmaceutical Sciences, Bundoora, Victoria 3083, Australia
    Expert Opin Pharmacother 9:2727-31. 2008
    ..Orlistat and sibutramine are the drugs used at present for weight loss, but they both have a relatively modest effect...
  2. ncbi request reprint Is tocilizumab an option for the treatment of arthritis?
    Sheila A Doggrell
    RMIT University, School of Medical Sciences, Discipline of Pharmaceutical Sciences, Bundoora, VIC3083, Australia
    Expert Opin Pharmacother 9:2009-13. 2008
    ..Tocilizumab is a humanised monoclonal antibody that binds to both forms of interleukin-6 receptor that has recently been used in Phase III trials in rheumatoid arthritis and systemic-onset juvenile idiopathic arthritis...
  3. ncbi request reprint Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?
    Sheila A Doggrell
    RMIT University, Pharmaceutical Sciences, School of Medical Sciences, PO Box 71, Victoria 3083, Australia
    Expert Opin Pharmacother 9:405-20. 2008
    ..Unless the thiazolidinediones are shown to improve cardiovascular or other outcomes (e.g., renal) in the next few years, their continued use in T2DM should be questioned...
  4. ncbi request reprint Celecoxib to prevent restenosis--results from the COREA-TAXUS trial
    Sheila A Doggrell
    RMIT University, Discipline of Pharmaceutical Sciences, School of Medical Sciences, Bundoora, Victoria 3083, Australia
    Expert Opin Pharmacother 9:339-41. 2008
    ..In conclusion, this is an excellent demonstration of translating a mechanism of action of a drug into a clinical use...
  5. ncbi request reprint Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide
    Sheila A Doggrell
    School of Science, Faculty of Education, Health and Science, Charles Darwin University, Darwin, Northern Territory 0909, Australia
    Rev Recent Clin Trials 2:77-84. 2007
    ..In conclusion, exenatide represents a new and beneficial addition to the medicines used to treat type 2 diabetes...
  6. ncbi request reprint Recent evidence of sustained benefit with exenatide in Type 2 diabetes
    Sheila A Doggrell
    School of Science, Charles Darwin University, Casuarina, Northern Territory 0811, Australia
    Expert Opin Pharmacother 7:2003-6. 2006
    ..9 kg) and those taking metformin and a sulfonylurea (4.1 kg). In conclusion, extension studies have confirmed that exenatide is an exciting new and useful medicine for Type 2 diabetes...
  7. ncbi request reprint Phosphoinositide 3-kinase-gamma as a target in rheumatoid arthritis and systemic lupus
    Sheila A Doggrell
    Charles Darwin University, School of Science, Casuarina, NT 0811, Australia
    Expert Opin Ther Targets 10:627-30. 2006
  8. ncbi request reprint Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?
    Sheila A Doggrell
    School of Science, Charles Darwin University, PO Box 41246, Casuarina, Northern Territory 0811, Australia
    Expert Opin Pharmacother 7:1229-33. 2006
    ..However, there is also some evidence that muraglitazar has detrimental effects on the cardiovascular system. Before muraglitazar is widely used in the treatment of Type 2 diabetes, more safety testing needs to be undertaken...
  9. ncbi request reprint Inhibition of RANKL: a new approach to the treatment of osteoporosis
    Sheila A Doggrell
    School of Science, Charles Darwin University, Casuarina, Northern Territory 0811, Australia
    Expert Opin Pharmacother 7:1097-100. 2006
  10. ncbi request reprint Is exenatide advancing the treatment of type 2 diabetes?
    Sheila A Doggrell
    Division of Health Practice, Auckland University of Technology Akoranga Campus, Northcote, Auckland, New Zealand
    Expert Opin Pharmacother 7:109-12. 2006
    ..In both trials, exenatide 5 and 10 microg s.c. was shown to improve glycaemic control, with few adverse events. Exenatide represents a new and useful addition to the medicines used to treat Type 2 diabetes...
  11. ncbi request reprint Editorial overview: The 'sartans': is it premature to consider PPARgamma receptor agonism a bonus?
    Sheila A Doggrell
    Curr Opin Investig Drugs 6:242-4. 2005
  12. ncbi request reprint The safety of lumiracoxib when used in the treatment of arthritis
    Sheila A Doggrell
    The University of Queensland, School of Biomedical Sciences, Australia
    Expert Opin Pharmacother 6:347-50. 2005
  13. ncbi request reprint Which drug combination for colorectal cancer?
    Sheila A Doggrell
    The University of Queensland, School of Biomedical Sciences, QLD 4072, Australia
    Expert Opin Pharmacother 5:2621-4. 2004
    ..Bevacizumab is likely to become part of the standard therapy for metastatic CRC...
  14. ncbi request reprint Telmisartan - killing two birds with one stone
    Sheila A Doggrell
    School of Biomedical Sciences, University of Queensland, QLD 4072, Australia
    Expert Opin Pharmacother 5:2397-400. 2004
    ..Thus, telmisartan, an AT(1)-receptor antagonist and PPARgamma agonist, represents the prototype of a new approach to treating coexisting diabetes and hypertension, which needs to be evaluated clinically...
  15. ncbi request reprint Vascular biology support for the use of bevacizumab in colorectal cancer
    Sheila A Doggrell
    Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand
    Expert Opin Investig Drugs 13:703-5. 2004
    ..These effects of bevacizumab on the vascular biology of tumours probably underlie the progression and survival benefits observed in clinical trials of colorectal cancer...
  16. ncbi request reprint Efalizumab for psoriasis?
    Sheila A Doggrell
    Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand
    Expert Opin Investig Drugs 13:551-4. 2004
    ..Direct comparative clinical trials will be needed to ascertain which of these agents provides the maximal improvement with the minimal incidence of side effects...
  17. ncbi request reprint Is natalizumab a breakthrough in the treatment of multiple sclerosis?
    Sheila A Doggrell
    School of Biomedical Sciences, The University of Queensland, QLD 4072, Australia
    Expert Opin Pharmacother 4:999-1001. 2003
    ..However, there were no changes in the Expanded Disability Status Scale scores in any of the groups. Natalizumab was well-tolerated. Thus, the initial results with natalizumab treatment over 6 months in multiple sclerosis are encouraging...
  18. ncbi request reprint TACE inhibition: a new approach to treating inflammation
    Sheila A Doggrell
    Department of Physiology and Pharmacology, School of Biomedical Sciences, The University of Queensland, QLD 4072, Australia
    Expert Opin Investig Drugs 11:1003-6. 2002
    ..Further longer-term studies of GW3333 in animal models are required to determine whether its benefit is maintained. TACE inhibition may represent a new approach to treating inflammation...
  19. ncbi request reprint Metformin & lifestyle intervention prevent Type 2 diabetes: lifestyle intervention has the greater effect
    Sheila A Doggrell
    Department of Physiology and Pharmacology, School of Biomedical Sciences, University of Queensland, 4072 Australia
    Expert Opin Pharmacother 3:1011-3. 2002
    ..Both intensive lifestyle intervention and metformin reduced the incidence of diabetes, with the lifestyle intervention having the greater effect...